News

Novo Nordisk stock posts worst week since 2021, but analysts see a bigger problem ahead
Novo Nordisk stock plunges 30% after forecast cut, CEO shakeup, and rising competition hit investor confidence.
Ozempic Maker’s Stock Plunges 20% After Profit Warning
Novo Nordisk slashed its financial forecasts as it struggled to fight off competition in the United States. It also named a ...
Novo Nordisk Cut Its Outlook and Named a New CEO. Its Stock Is Plummeting
U.S.-listed shares of Novo Nordisk (NVO) sank roughly 20% in premarket trading after the Danish drugmaker cut its full-year ...
Novo Nordisk: Is This An Overreaction Or The End Of The GLP-1 Fairy Tale?
Novo Nordisk faces slowing demand, rising competition, and CEO transition. Learn about challenges impacting its growth and ...
A Medicare experiment could change who gets Ozempic
A five-year experiment aims to open access to blockbuster GLP‑1 drugs for obesity, something advocates have pushed for years.
New tariffs could raise prices of Ozempic, Wegovy
Some of the most recognizable brand names that could be impacted by new tariffs include Ozempic and Wegovy, two injectable ...
Opinion
Novo Nordisk’s Weight Loss Lesson
Furious competition in GLP-1 drugs rebuts the anti-pharma crowd.
Medicare and Medicaid move toward covering Ozempic and other weight loss drugs
Medicare and Medicaid could expand coverage of GLP-1 drugs, such as Ozempic and Wegovy, and pay for patients’ use of the ...